Eyexora Debuts to Accelerate Global Ophthalmology Innovation with Hub-and-Spoke Model
Eyexora announced its official launch with the goal of speeding innovation in ophthalmology using a hub-and-spoke operational model. Backed by a seed round led by life sciences investor ClavystBio and supported by ophthalmology experts, the US-based startup aims to build a diversified global portfolio of anterior and posterior segment therapeutics as well as ophthalmic devices—addressing a $50 billion market serving more than two billion patients worldwide.
According to the company, Eyexora consolidates scientific, clinical, regulatory, and commercial expertise into a central “hub,” which provides shared infrastructure and resources to multiple therapeutic subsidiaries. Each subsidiary will house a distinct therapeutic or technology program, enabling scalable growth while lowering development risk.
The model blends validated mechanisms with high-impact “moonshot” programs and is designed for continuous replenishment of clinic-ready assets sourced from global clinician-scientists and academic incubators. Eyexora’s initial assets are in-licensed from the Singapore Eye Research Institute (SERI), and the company is pursuing partnerships in Singapore and Europe as it establishes a global footprint.
“Traditional ophthalmology drug development has been dominated by single-asset pipelines, making innovation slow, costly, and high-risk,” said Theresa Heah, MD, MBA, Co-Founder, Vice Chair, and CEO of Eyexora. “Eyexora is built to change that by bringing the right structure, global partnerships, and deep domain expertise together to deliver transformative treatments faster, smarter, and at scale.”
Eyexora was co-founded by ophthalmology leaders:
Bill Link, PhD, Chairman – Renowned investor and entrepreneur, founder of Versant Ventures, AMO, and Flying-L Partners
Theresa Heah, MD, MBA, Vice Chair and CEO – Former senior executive at Aerie Pharmaceuticals, Kriya, AGTC, Sanofi-Fovea, and Bayer
"Ophthalmology has no shortage of brilliant science, but the industry is ripe for a new structure to optimize the translation of science into patient impact,” said Dr. Link. “With the right team, partners, and science, Eyexora is positioned to change the innovation curve for patients globally.”